| Bioactivity | Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research[1]. |
| Name | Divozilimab |
| CAS | 2254061-60-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. O V Boyko, et al. Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(10. Vyp. 2):87-95. |